MétaCan
Menu
Cohort builder

4,299,418 works, Canadian by any of four routes.

Every filter state is a URL; the URL is the query; the query is citable via /q/⟨hash⟩. The page, the API and the export parse the same parameters.

The current cohort, streamed from the database: every work column, the machine labels, the provisional scores, and the per-row validation status. Exports are capped at 100,000 rows. Mints a permanent /q/ link for this exact query. The same filters always produce the same link, whoever asks.

Search term
Author
Year range
Sort
Language
Type
Field
Venue
Topic
HER2/EGFR in Cancer Research
Retraction
Abstract
Evidence source
Study design
Label agreement
Label status

Direct Codex and Gemma labels are unvalidated and sparse. Distilled predictions cover the full frame and are also unvalidated. Choose the evidence source explicitly; absence of a direct label is never a negative label.

affaffiliation
fundfunder
venuejournal
aboutaboutness

The four routes compose: require the funder route and exclude affiliation to get the funder-only stratum no affiliation-based frame ever sees.

1,303 results · 1 filter active ·
Results by year
20002025
Publication date
Categories
Machine labels · sparse coverage
Evidence
Language
Type
Citations
An unlabeled work is unknown, not a negative. Label coverage is reported on every query.
1,303 works in the cohort · of 4,299,418page 3 of 27

Labels cover 3 of 1,303 works in this cohort. The rest are unlabeled, which is not a negative label: the label table is sparse today and grows as labeling rounds land.

Distilled predictions cover 1,303 of 1,303 works in this cohort. Predictions are machine_predicted_unvalidated teacher distillation outputs. Candidate is the union; consensus is the intersection.

affno abstractunlabeled
Tissue Microarrays in Clinical Oncology
David Voduc, Challayne Kenney, Torsten O. Nielsen
2008· review· en· Seminars in Radiation Oncology· Medicine
distilled prediction:candidate · metaepi_narrow+research_integrity+insufficient_payloadconsensus · research_integrity
145
citations
affunlabeled
First results from the phase III ALTTO trial (BIG 2-06; NCCTG [Alliance] N063D) comparing one year of anti-HER2 therapy with lapatinib alone (L), trastuzumab alone (T), their sequence (T→L), or their combination (T+L) in the adjuvant treatment of HER2-positive early breast cancer (EBC).
Martine Piccart, Andrew Holmes, José Baselga, Evandro de Azambuja, Amylou C. Dueck, Giuseppe Viale +14 more
2014· article· en· Journal of Clinical Oncology· Medicine
distilled prediction:candidate · noneconsensus · none
144
citations
afffundunlabeled
Expression and Nuclear Localization of ErbB3 in Prostate Cancer
Ismaël Hervé Koumakpayi, Jean‐Simon Diallo, Cécile Le Page, Laurent Lessard, Martin Gleave, Louis R. Bégin +2 more
2006· article· en· Clinical Cancer Research· Medicine
distilled prediction:candidate · insufficient_payloadconsensus · none
143
citations
affno abstractunlabeled
Memo mediates ErbB2-driven cell motility
Romina Marone, Daniel Heß, David Dankort, William J. Muller, Nancy E. Hynes, Ali Badache
2004· article· en· Nature Cell Biology· Medicine
distilled prediction:candidate · noneconsensus · none
142
citations
affunlabeled
Emerging Technologies for Assessing HER2 Amplification
Frédérique Penault‐Llorca, Michael Bilous, Mitch Dowsett, Wedad Hanna, R. Yoshiyuki Osamura, Josef Rüschoff +1 more
2009· review· en· American Journal of Clinical Pathology· Medicine
distilled prediction:candidate · metaresearch+metaepi_narrow+research_integrityconsensus · none
140
citations
affunlabeled
Datopotamab Deruxtecan Versus Chemotherapy in Previously Treated Inoperable/Metastatic Hormone Receptor–Positive Human Epidermal Growth Factor Receptor 2–Negative Breast Cancer: Primary Results From TROPION-Breast01
Aditya Bardia, Komal Jhaveri, Seock‐Ah Im, Sònia Pernas, Michelino De Laurentiis, Shusen Wang +174 more
2024· article· en· Journal of Clinical Oncology· Medicine
distilled prediction:candidate · metaepi_narrow+research_integrity+insufficient_payloadconsensus · none
140
citations
affunlabeled
Standardization of Positive Controls in Diagnostic Immunohistochemistry
Emina Torlakovic, Søren Nielsen, Glenn Francis, J. R. Garratt, C. Blake Gilks, Jeffrey D. Goldsmith +9 more
2014· review· en· Applied immunohistochemistry & molecular morphology· Medicine
distilled prediction:candidate · metaepi_narrow+research_integrityconsensus · none
139
citations
affno abstractunlabeled
LBA21 KEYNOTE-756: Phase III study of neoadjuvant pembrolizumab (pembro) or placebo (pbo) + chemotherapy (chemo), followed by adjuvant pembro or pbo + endocrine therapy (ET) for early-stage high-risk ER+/HER2– breast cancer
Fátima Cardoso, Heather L. McArthur, Peter Schmid, Javier Cortés, Nadia Harbeck, Melinda L. Telli +14 more
2023· article· en· Annals of Oncology· Medicine
distilled prediction:candidate · metaepi_narrow+insufficient_payloadconsensus · none
134
citations
afffundaboutunlabeled
Selection of Optimal Adjuvant Chemotherapy Regimens for Human Epidermal Growth Factor Receptor 2 (HER2) –Negative and Adjuvant Targeted Therapy for HER2-Positive Breast Cancers: An American Society of Clinical Oncology Guideline Adaptation of the Cancer Care Ontario Clinical Practice Guideline
Neelima Denduluri, Mark R. Somerfield, Andrea Eisen, Jamie N. Holloway, Arti Hurria, Tari A. King +5 more
2016· article· en· Journal of Clinical Oncology· Medicine
distilled prediction:candidate · metaresearchconsensus · none
129
citations
affunlabeled
ErbB2 Is Required for Muscle Spindle and Myoblast Cell Survival
Eran R. Andrechek, W. Rod Hardy, Adele Girgis-Gabardo, Robert L. Perry, Richard Butler, Frank L. Graham +3 more
2002· article· en· Molecular and Cellular Biology· Medicine
distilled prediction:candidate · noneconsensus · none
126
citations
affunlabeled
Quantitative Justification of the Change From 10% to 30% for Human Epidermal Growth Factor Receptor 2 Scoring in the American Society of Clinical Oncology/College of American Pathologists Guidelines: Tumor Heterogeneity in Breast Cancer and Its Implications for Tissue Microarray–Based Assessment of Outcome
C. Moeder, Jennifer M. Giltnane, Malini Harigopal, Annette M. Molinaro, Andrew Robinson, Karen Gelmon +3 more
2007· article· en· Journal of Clinical Oncology· Medicine
distilled prediction:candidate · noneconsensus · none
109
citations

How this was built: Screen · Findings · About